Fig. 2From: Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysisForest plot of the association between Eastern Cooperative Oncology Group and hyperprogressive disease. OR, odd ratio; CI, confidence intervalBack to article page